Weekly Research Analysts’ Ratings Changes for Delcath Systems (DCTH)

Several brokerages have updated their recommendations and price targets on shares of Delcath Systems (NASDAQ: DCTH) in the last few weeks:

• 10/25/2024 – Delcath Systems was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/18/2024 – Delcath Systems had its “buy” rating reaffirmed by analysts at Stephens.
• 10/18/2024 – Delcath Systems had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $21.00 price target on the stock.
• 10/18/2024 – Delcath Systems had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 10/17/2024 – Delcath Systems was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 9/27/2024 – Delcath Systems was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/19/2024 – Delcath Systems was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 9/9/2024 – Delcath Systems was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Delcath Systems Stock Performance

DCTH stock opened at $10.94 on Friday. The stock has a market capitalization of $304.02 million, a P/E ratio of -4.29 and a beta of 0.75. Delcath Systems, Inc. has a one year low of $2.25 and a one year high of $11.74. The company has a 50 day moving average price of $9.78 and a two-hundred day moving average price of $8.27.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The company had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the prior year, the firm earned ($0.58) earnings per share. Research analysts forecast that Delcath Systems, Inc. will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new position in shares of Delcath Systems during the 2nd quarter valued at $694,000. Vanguard Group Inc. lifted its holdings in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after buying an additional 161,678 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the 2nd quarter worth $370,000. Shellback Capital LP acquired a new position in Delcath Systems in the 2nd quarter worth $1,353,000. Finally, Legato Capital Management LLC acquired a new position in Delcath Systems in the 2nd quarter worth $966,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.